Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts

Ultragenyx Pharmaceutical remains a speculative conviction hold (3/5) as its commercial base funds a robust late-stage rare disease pipeline. Multiple pivotal catalysts in 2026–2027, including GTX-102, DTX401, and UX111, could drive significant revenue growth and shift sentiment. Conservative U.S.-only modeling suggests $1.5B–$2.4B peak annual revenue potential from late-stage programs, with Street estimates supporting multi-bagger upside.